Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Derré L, et al. Among authors: jichlinski p. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. J Immunother Cancer. 2023. PMID: 38101861 Free PMC article.
Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M, Valerio M, Mampuya A, Rakauskas A, Berthold D, Tawadros T, Meuwly JY, Heym L, Duclos F, Vallet V, Zeverino M, Jichlinski P, Prior J, Roth B, Bourhis J, Herrera FG. Cloitre M, et al. Among authors: jichlinski p. Br J Radiol. 2023 Apr 1;96(1145):20220803. doi: 10.1259/bjr.20220803. Epub 2023 Mar 3. Br J Radiol. 2023. PMID: 36745031 Free PMC article. Clinical Trial.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I, Derré L, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias S, Dartiguenave F, Masnada A, Texeira-Pereira C, Benmerzoug S, Chevalier M, Domingos-Pereira S, Nguyen S, Polak L, Schneider A, Roth B, Jichlinski P, Nardelli-Haefliger D. Lucca I, et al. Among authors: jichlinski p. Eur Urol Open Sci. 2022 Oct 3;45:55-58. doi: 10.1016/j.euros.2022.09.004. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36212980 Free PMC article.
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias SC, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Nguyen S, et al. Among authors: jichlinski p. J Immunother Cancer. 2022 Aug;10(8):e004880. doi: 10.1136/jitc-2022-004880. J Immunother Cancer. 2022. PMID: 36002184 Free PMC article.
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: jichlinski p. Eur Urol Open Sci. 2021 Nov 18;34:79-82. doi: 10.1016/j.euros.2021.10.001. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34825225 Free PMC article.
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A, Tawadros T, Lucca I, Herrera F, Bourhis J, Burruni R, Gomes MN, Codeluppi C, Jolliet L, La Rosa S, Meuwly JY, Jichlinski P, Berthold D, Valerio M. Rakauskas A, et al. Among authors: jichlinski p. Investig Clin Urol. 2021 Jul;62(4):416-422. doi: 10.4111/icu.20200601. Investig Clin Urol. 2021. PMID: 34190436 Free PMC article. Clinical Trial.
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Verardo M, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: jichlinski p. Eur Urol Focus. 2022 May;8(3):748-751. doi: 10.1016/j.euf.2021.06.001. Epub 2021 Jun 17. Eur Urol Focus. 2022. PMID: 34147404 Free article.
The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A, Venderink W, Patak MA, Möckel C, Fehr JL, Jichlinski P, Porcellini B, Lucca I, Futterer J, Valerio M. Perrin A, et al. Among authors: jichlinski p. Urol Oncol. 2021 May;39(5):297.e9-297.e16. doi: 10.1016/j.urolonc.2020.11.041. Epub 2020 Dec 17. Urol Oncol. 2021. PMID: 33341358 Free article.
206 results